Encapsulation commercially available compounds

This problem can easily be solved by using stabilized aluminum pigments. Pigments inhibited with phosphoorganic compounds, chrome treatments or by organic or inorganic encapsulation are commercially available. Further possibilities are published in Ref [5.183]. 

As another example of the special type of polymer blend studied with EM, the SEM images of a biopolymer-based compound are presented in Figure 17.12. Recently, the encapsulation of curcumin in submicrometer spray-dried chitosan/ Tween 20 particles was evaluated using SEM imaging [84]. Tween 20 was a commercially available version of polyethylene glycol sorbitan monolaurate. The encapsulation of curcumin is important, as its optimal delivery in medicinal... 

With the comprehensive research base that has developed in this area, if therapeutic peptides or proteins can be successfully and, to some extent, economically microencapsulated to produce a homogeneous and stable dmg delivery system, the potential for a successful system is unchallengeable. However, although many systems are in the process ofpreclinical and even early clinical trials, there are still many issues in this field that need to be addressed and resolved. Certain studies are performed with compounds that, for a number of reasons, are not viable commercially for oral delivery, usually because of related issues such as dose, cost, and encapsulation efficiency. Although many such studies are cited as proof of concept, it is extremely difficult to define a model peptide or protein with which to optimize a delivery system. Detailed scientific information on mechanisms of action is also lacking in many circumstances and, if available, would allow logical approaches to system optimization and ultimately potential widespread system application. 

---